title: [2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research].
abstract: 2-chlorodeoxyadenosine (2-CDA) is very effective in the treatment of patients with hairy-cell leukaemia, with an overall response rate of 80-95%. The standard treatment is a continuous intravenous infusion for 7 days. The bioavailability of 2-CDA after subcutaneous injection is 100%, but the concentration-time profile is completely different compared to continuous intravenous administration. In the present study we compared the intravenous standard treatment (group 1, n = 22; 0.1 mg/kg/d for 7 days, civ.) with subcutaneous administration of 2-CDA (group 2, n = 62; 0.14 mg/kg/d for 5 days, s.c.) in patients with hairy-cell leukaemia. In group 1, 96% (21/22) of patients responded to 2-CDA (complete remission 73%, partial remission 23%) and in the second group 97% were responsive (complete response 76%, 47/62; partial remission 21%, 13/62). The percentage for moderate and severe infections in the trial with intravenous and subcutaneous treatment was 14% and 26% respectively (p = 0.37). We conclude that subcutaneous administration of 2-CDA in patients with hairy-cell leukaemia is feasible and economical and results in comparable responses and toxicity compared to the intravenous standard treatment.
authors.affiliation: Institut für Medizinische Onkologie, Inselspital Bern. roland.sperb@insel.ch
authors.forename: R A
authors.initials: RA
authors.lastname: Sperb
authors.forename: A
authors.initials: A
authors.lastname: von Rohr
authors.forename: D
authors.initials: D
authors.lastname: Ratschiller
authors.forename: M
authors.initials: M
authors.lastname: Bacchi
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: U
authors.initials: U
authors.lastname: Hess
authors.forename: T
authors.initials: T
authors.lastname: Cerny
authors.forename: A
authors.initials: A
authors.lastname: Tobler
authors.forename: D C
authors.initials: DC
authors.lastname: Betticher
mesh_terms: D015762:2-Chloroadenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D003839:Deoxyadenosines / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003839:Deoxyadenosines; D015762:2-Chloroadenosine; C055994:2-chloro-3'-deoxyadenosine
vernacular_title: 2-CDA bei der Behandlung der Haarzell-Leukämie: ein Vergleich zwischen intravenöser und subkutaner Verabreichung. Schweizerische Arbeitsgemeinschaft für angewandte Krebsforschung.